Related Experiment Video
Updated: Nov 20, 2025

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
Risk assessment in precapillary pulmonary hypertension: a comparative analysis
Thomas Sonnweber1, Eva-Maria Schneider1, Manfred Nairz1
1Department of Internal Medicine II, Medical University Innsbruck, Anichstraße 35, 6020, Innsbruck, Tyrol, Austria.
Accurate mortality risk prediction in precapillary pulmonary hypertension (PH) is crucial. Current risk tools struggle with intermediate-to-high risk patients, but expanded non-invasive evaluations improve accuracy.
Area of Science:
- Cardiology
- Pulmonary Medicine
- Medical Statistics
Background:
- Risk stratification is vital for managing precapillary pulmonary hypertension (PH).
- Accurate mortality risk assessment guides treatment decisions in PH patients.
- Current risk stratification tools require evaluation for improved accuracy.
Purpose of the Study:
- To compare the accuracy of different PH risk stratification tools.
- To evaluate the significance of specific risk parameters in PH mortality prediction.
- To identify areas for improvement in risk assessment for PH patients.
Main Methods:
- Retrospective longitudinal observational cohort study.
- Evaluation of seven risk assessment approaches based on current PH guidelines.
- Multi-parametric risk stratification at baseline and follow-up, analyzed with Cox hazard models.
Main Results:
- Existing risk models accurately predicted mortality in precapillary PH.
- Right-heart catheterization parameters were not essential for risk prediction.
- Non-invasive follow-up assessments significantly enhanced risk estimation accuracy, especially in intermediate- and high-risk groups.
Conclusions:
- Current abbreviated risk tools (ESC/ERS, REVEAL 2.0/Lite 2) lack precision for intermediate-to-high risk PH.
- An expanded non-invasive evaluation, including age and right atrium area, significantly improves mortality risk prediction.
- Refined risk stratification is needed for better PH patient management.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Measurement of Blood Pressure
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

